Related Experiment Videos
Intron A (interferon-alpha-2b recombinant) for injection/Schering-Plough Corporation
Summary
Intron A, a genetically engineered interferon-alpha-2b recombinant, is now approved for treating chronic hepatitis C. This marks a significant advance, offering the first effective treatment for this persistent viral liver disease.
Area of Science:
- Biotechnology
- Hepatology
- Virology
Background:
- Chronic non-A, non-B hepatitis (hepatitis C) has lacked effective treatment options.
- Interferon-alpha-2b recombinant is a genetically engineered antiviral protein.
Purpose of the Study:
- To announce the approval and potential of Intron A (Interferon-alpha-2b Recombinant) for treating chronic hepatitis C.
Main Methods:
- Utilized recombinant DNA technology to produce Interferon-alpha-2b.
- Clinical evaluation of the efficacy of Intron A in patients with chronic hepatitis C.
Main Results:
- Intron A (Interferon-alpha-2b Recombinant) has received US approval for chronic hepatitis C treatment.
- Represents a novel therapeutic approach for a previously untreatable condition.
Conclusions:
- Intron A signifies a breakthrough in managing chronic hepatitis C.
- Offers a new hope for patients with this persistent viral infection.